RESUMO
Intra-abdominal fat mass, or central adiposity, and cardiovascular risk are strongly correlated. Adipose tissue is an endocrine organ that secretes hormones and cytokines influencing appetite, energy metabolism, and atherosclerosis. Rimonabant is the first selective blocker of the cannabinoid-1 receptor in development for the treatment of obesity, diabetes mellitus typ 2, and cardiometabolic risk factors. This article provides an review of efficacy of rimonabant the first selective blocker of the cannabinoid-1 receptor.
Assuntos
Antagonistas de Receptores de Canabinoides , Doenças Cardiovasculares/prevenção & controle , Diabetes Mellitus Tipo 2/tratamento farmacológico , Angiopatias Diabéticas/prevenção & controle , Síndrome Metabólica/tratamento farmacológico , Obesidade/tratamento farmacológico , Piperidinas/uso terapêutico , Pirazóis/uso terapêutico , Humanos , Obesidade/complicações , Ensaios Clínicos Controlados Aleatórios como Assunto , RimonabantoRESUMO
Acute left main coronary artery (LMCA) occlusion is associated with a high mortality rate. The majority of patients with this clinical condition die suddenly or from cardiogenic shock. We report a case of cardiogenic shock resulting from acute main coronary occlusion. Emergency cardiac catheterization was performed and coronary angiography showed a totally occluded LMCA. Prompt revascularization by means of primary LMCA stenting was successful and the patient was discharged 16 days later without neurological deficit or clinical signs of heart failure. We suggest that the rapid coronary angiography followed by angioplasty and primary stent implantation was instrumental in saving this patient's life.